CLVLY 주가 차트
CLVLY 수입
Clinuvel Pharmaceuticals Limited
$6.82
-0.29%
$-0.01
종가: May 08, 16:00:00 GMT-4
$6.82
0%
$0
애프터마켓: May 08, 20:00:00 GMT-4
뒤로
Clinuvel Pharmaceuticals Limited (CLVLY) 수입
최신 수익 결과: Q2 '26
보고됨: 2026-02-26
역사적 수익
분기별
연간
EPS
수익
Earnings FAQ
CLVLY의 최근 주당순이익(EPS)은 예상과 비교하여 어떤가요?
Clinuvel Pharmaceuticals Limited CLVLY의 지난 분기 매출 실적은 어땠나요?
Clinuvel Pharmaceuticals Limited의 매출 추정치는 얼마인가요?
Clinuvel Pharmaceuticals Limited의 수익 품질 점수는 얼마인가요?
Clinuvel Pharmaceuticals Limited는 언제 수익을 보고하나요?
Clinuvel Pharmaceuticals Limited의 예상 수익은 얼마인가요?
Clinuvel Pharmaceuticals Limited은 수익 기대치를 충족했나요?
주요 통계
이전 종가
$6.84
시가
$6.81
일일 범위
$6.81 - $6.82
52주 범위
$6 - $9
거래량
440
평균 거래량
2.1K
배당수익률
--
EPS(TTM)
0.46
시가총액
$343.9M
Clinuvel Pharmaceuticals Ltd.란 무엇인가요?
Clinuvel Pharmaceuticals Ltd. operates as a biopharmaceutical company. The company is headquartered in Melbourne, Victoria. The company went IPO on 2001-02-13. The company is focused on developing and commercializing treatments for patients with genetic, metabolic, systemic, and life-threatening, acute disorders, as well as healthcare solutions for specialized populations. Its lead therapy, SCENESSE (afamelanotide 16mg), is approved for commercial distribution in Europe, the United States of America, Israel, and Australia as the first systemic photoprotective drug for the prevention of phototoxicity (anaphylactoid reactions and burns) in adult patients with erythropoietic protoporphyria (EPP). The company has operations in Europe, Singapore, and the United States of America. The company develops and manufactures NEURACTHEL (adrenocorticotropic hormone) in different formulations, to target neurological, endocrinological, and degenerative disorders. Its pharmaceutical product, PRENUMBRA, has been developed, and its use is to be expanded in the clinic from stroke to Parkinson's.
